Uncategorized
Syntax Bio Partners with Breakthrough T1D for diabetes research
The good news for our Chicago-based portfolio company, Syntax Bio, keeps coming! Syntax receiving an award of up to $856K from Breakthrough T1D to advance a pancreatic beta cell therapy for type 1 diabetes.
Get in touch
Chicago | Boston | Atlanta | Houston
©2026 Portal Innovations, LLC
Sign up for our monthly newsletter
Stay up-to-date on the latest VC, biotech, and med tech news in Chicago and across the U.S. Sign up with your email address below to get our monthly newsletter delivered to your inbox!